高血压立体化管理的优选药物0218课程实例.pptxVIP

美卡素?是高血压 “立体化”管理的优选ARB;我国心脑血管事件高发;;为更多减少心脑血管事件应进行高血压立体化管理;;替米沙坦强效降压，优于氯沙坦;替米沙坦强效降压，优于缬沙坦;Nishimura T, et al. Clin Exp Hypertens. 2005, 27(6):477-89.;Sasaki T, et al. Hypertens Res. 2008, 31(5):921-9;替米沙坦， 24小时强效降压优于氯沙坦;;Nishimura T, et al. Clin Exp Hypertens. 2005, 27(6):477-89.;Galzerano, et al. Vascular Health and Risk Management . 2010; 6 :113–133;长期单独应用替米沙坦以及联合应用 替米沙坦与雷米普利多中心终点试验;Argentina France The Netherlands Spain Australia Germany New Zealand Sweden Austria Greece Norway Switzerland Belgium Hong Kong Philippines Taiwan Brazil Hungary Poland Thailand Canada Ireland Portugal Turkey China Italy Russia UK Czech Republic Korea Singapore Ukraine Denmark Malaysia Slovakia United Arab Emirates Finland Mexico South Africa USA;N Engl J Med 2008;358:1547-59.;;;替米沙坦可显著降低糖尿病患者因大血管并发症入院的风险达15%;;ARB的心血管保护研究结果不一致其它几个ARB的心血管证据集中在肾脏保护和心衰/心梗后;缬沙坦两大心脏研究JIKEI Heart和KYOTO Heart文章被撤销;ROADMAP和ORIENT两大研究显示：奥美沙坦升高心血管死亡风险;IDNT和I-PRESERVE两大研究均未能证实厄贝沙坦可降低心血管风险;ELITE II和OPTIMAAL两大研究均未能证实氯沙坦可降低心血管风险;;Burnier, Brunner. Lancet 2000;355:637–645;TheodoreW. Kurtz and Michal Pravenec. Journal of Hypertension 2004, 22:2253–2261;美卡素?契合立体化血压管理理念是优化我国高血压管理的理想选择